+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Modality, By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • July 2023
  • Region: Global
  • Grand View Research
  • ID: 5853840
Description Jump to:
The global RNA therapy clinical trials market size is expected to reach USD 3.5 billion by 2030. The market is expected to grow at a CAGR of 3.84% from 2023 to 2030. The growth of the market in emerging countries is due to escalating biotechnology and pharmaceutical companies, the increasing burden of infectious and rare diseases, the growing success rate of RNA-based covid-19 vaccines, regulatory approval, and demand for personalized medicines drive the market growth.

Besides, RNA therapy acts as a promising therapeutic approach for the treatment or prevention of diseases leading to a rise in several RNA clinical trials. Additionally, long-term research activities on various types of RNAs, and the ability of RNA to treat various human diseases and disorders have led to strong demand for the market. Also, the potential benefit of RNA therapy wherein RNA itself serves as either a drug or a target provides acts as an innovative approach for developing new drugs for rare or difficult-to-treat diseases.

Globally, infectious diseases and rare diseases remain the leading cause of death, which has gained the increased attention of biotechnology and pharmaceutical companies to develop new drugs. This led to the rise in the innovation of RNA-based therapy creating immense requirements for RNA therapy clinical trials. Additionally, rare diseases remain the top targeted therapeutic area by RNA therapies.

Furthermore, according to the US Food & Drug Administration, in December 2022, over 7,000 rare diseases affected more than 30 million people in the U.S. whereas according to European Commission as of February 2023, up to 36 million European population live with a rare disease. There are 6000+ distinct rare diseases in the EU. Likewise, the increasing understanding of RNA functions and their roles in disease prevention has promoted various RNAs application.

The COVID-19 pandemic has greatly impacted the growth of the RNA therapy clinical trials market. The sudden focus of pharmaceutical and biotechnology companies on the development of the vaccine, research, and development activities had certainly disrupted the RNA clinical trials across the globe. However, the increasing interest of researchers to develop an RNA-based COVID-19 vaccine has supported the market with positive growth. Additionally, it has also sparked an interest in RNA use against other infectious diseases and oncology indications. These factors drive the growth of the market.

Furthermore, the key participants engage in strategies such as partnerships, agreements, collaborations, and launches, to expand their global footprints and product portfolio. For instance, in March 2021, IQVIA Company announced the collaboration with Janssen Research & Development, LLC for Phase 3 COVID-19 vaccine clinical trials. The studies will support both remote and on-site studies through a mix of virtual oversight, telehealth technologies, and digital patient engagement strategies.

RNA Therapy Clinical Trail Market Report Highlights

  • The messenger RNA segment held the largest revenue share of 35.7% in 2022 owing to increased researchers' study in gene expression, technology advancement has contributed to the segment growth
  • The Phase II segment dominated the RNA therapy clinical trials market with a revenue share of 41.3% in 2022. The effectiveness of RNA therapy and the safety of RNA clinical trials will drive segment growth
  • In 2022, the rare diseases segment dominated the market and accounted for a revenue share of 21.8%. The key factors contributing to the growth include the growing burden of various types of rare diseases. Also, R&D expenditures made by market players drive the market growth
  • North America held the largest revenue share of 36.6% in 2022. The presence of well-established market players, the increasing burden of rare diseases, growing research activities on RNA, rising number of clinical trials drive the regional growth
  • Additionally, constant innovation and an emerging number of clinical studies and trials drive the market growth in the region. For instance, in December 2022, Moderna & Merck mentioned the phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 a personalized mRNA cancer vaccine with KEYTRUDA combination. It is an mRNA cancer vaccine for melanoma stage III/IV patient treatment
  • Key players dominating the market include IQVIA; Laboratory Corporation of America Holdings; ICON Plc; Charles River Laboratories International, Inc.; PPD Inc.; Syneos Health; Medpace Holdings, Inc.; Novotech; PAREXEL International Corp.; and Veristat, LLC

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.5. Market Driver Analysis
3.6. Market Restraint Analysis
3.7. Business Environment Analysis
3.7.1. SWOT Analysis
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Modality Business Analysis
4.1. RNA therapy clinical trials Market: Modality Movement Analysis
4.2. RNA interference
4.2.1. RNA interference Market, 2018 - 2030 (USD Million)
4.3. Antisense therapy
4.3.1. Antisense therapy Market, 2018 - 2030 (USD Million)
4.4. Messenger RNA
4.4.1. Messenger RNA Market, 2018 - 2030 (USD Million)
4.5. Oligonucleotide, non-antisense, non-RNAi
4.5.1. Oligonucleotide, non-antisense, non-RNAi Market, 2018 - 2030 (USD Million)
Chapter 5. Clinical Trials Phase Business Analysis
5.1. RNA therapy clinical trials Market: Clinical Trials Phase Movement Analysis
5.2. Phase I
5.2.1. Phase I Market, 2018 - 2030 (USD Million)
5.3. Phase II
5.3.1. Phase II Market, 2018 - 2030 (USD Million)
5.4. Phase III
5.4.1. Phase III Market, 2018 - 2030 (USD Million)
5.5. Phase IV
5.5.1. Phase IV Market, 2018 - 2030 (USD Million)
Chapter 6. Therapeutic Areas Business Analysis
6.1. RNA therapy clinical trials Market: Therapeutic Areas Movement Analysis
6.2. Rare Diseases
6.2.1. Rare Diseases Market, 2018 - 2030 (USD Million)
6.3. Anti-infective
6.3.1. Anti-infective Market, 2018 - 2030 (USD Million)
6.4. Anticancer
6.4.1. Anticancer Market, 2018 - 2030 (USD Million)
6.5. Neurological
6.5.1. Neurological Market, 2018 - 2030 (USD Million)
6.6. Alimentary/Metabolic
6.6.1. Alimentary/Metabolic Market, 2018 - 2030 (USD Million)
6.7. Musculoskeletal
6.7.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
6.8. Cardiovascular Respiratory
6.8.1. Cardiovascular Respiratory Market, 2018 - 2030 (USD Million)
6.9. Sensory
6.9.1. Sensor Market, 2018 - 2030 (USD Million)
6.10. Others
6.10.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. RNA therapy clinical trials Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Regulatory Framework
7.2.2.3. Competitive Scenario
7.2.2.4. U.S. RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Regulatory Framework
7.2.3.3. Competitive Scenario
7.2.3.4. Canada RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. UK RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Germany RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. France RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Italy RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Spain RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.7. Sweden
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Sweden RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.8. Norway
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Norway RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.3.9. Denmark
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Denmark RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Japan RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. China RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. India RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Australia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. South Korea RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Thailand RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Brazil RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Mexico RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Argentina RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. South Africa RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Saudi Arabia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. UAE RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Kuwait RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. Merger& Acquisition
8.2.2. Collaborations
8.2.3. New Product Launch
8.3. Participant’s overview
8.3.1. IQVIA
8.3.1.1. Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. ICON Plc
8.3.2.1. Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Laboratory Corporation of America Holdings
8.3.3.1. Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Charles River Laboratories International, Inc.
8.3.4.1. Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. PAREXEL International Corp.
8.3.5.1. Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Syneos Health
8.3.6.1. Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Medpace Holdings, Inc.
8.3.7.1. Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. PPD Inc.
8.3.8.1. Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Novotech
8.3.9.1. Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Veristat, LLC.
8.3.10.1. Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Leading Market Players Anticipated to Witness Highest Growth
Table 4 Global RNA Therapy Clinical Trials Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 8 North America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 10 North America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 11 North America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 12 U.S. RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 13 U.S. RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 14 U.S. RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 15 Canada RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 16 Canada RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 17 Canada RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 18 Europe RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 19 Europe RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 20 Europe RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 21 Europe RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 22 UK RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 23 UK RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 24 UK RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 25 Germany RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 26 Germany RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 27 Germany RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 28 France RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 29 France RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 30 France RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 31 Italy RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 32 Italy RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 33 Italy RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 34 Spain RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 35 Spain RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 36 Spain RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 37 Sweden RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 38 Sweden RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 39 Sweden RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 40 Norway RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 41 Norway RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 42 Norway RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 43 Denmark RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 44 Denmark RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 45 Denmark RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 46 Asia Pacific RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 47 Asia Pacific RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 48 Asia Pacific RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 49 Asia Pacific RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 50 Japan RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 51 Japan RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 52 Japan RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 53 China RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 54 China RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 55 China RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 56 India RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 57 India RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 58 India RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 59 Australia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 60 Australia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 61 Australia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 62 South Korea RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 63 South Korea RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 64 South Korea RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 65 Thailand RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 66 Thailand RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 67 Thailand RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 68 Latin America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 69 Latin America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 70 Latin America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 71 Latin America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 72 Brazil RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 73 Brazil RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 74 Brazil RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 75 Mexico RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 76 Mexico RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 77 Mexico RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 78 Argentina RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 79 Argentina RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 80 Argentina RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 81 Middle East and Africa RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
Table 82 Middle East and Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 83 Middle East and Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 84 Middle East and Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 85 South Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 86 South Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 87 South Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 88 Saudi Arabia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 91 UAE RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 92 UAE RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 93 UAE RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
Table 94 Kuwait RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
Table 95 Kuwait RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
Table 96 Kuwait RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
List of Figures
Fig. 1 RNA Therapy Clinical Trials Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook (2022)
Fig. 10 Strategy framework
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 RNA Therapy Clinical Trials Market: Modality movement analysis
Fig. 17 RNA Therapy Clinical Trials Market: Modality segment dashboard
Fig. 18 RNA Therapy Clinical Trials Market Modality outlook: Key takeaways
Fig. 19 RNA interference market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Antisense therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Messenger RNA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Oligonucleotide, non-antisense, non-RNAi market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 RNA Therapy Clinical Trials Market: Clinical Trials Phase movement analysis
Fig. 24 RNA Therapy Clinical Trials Market: Clinical Trials Phase segment dashboard
Fig. 25 RNA Therapy Clinical Trials Market: Clinical Trials Phase outlook: Key takeaways
Fig. 26 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 RNA Therapy Clinical Trials Market: Therapeutic Areas movement analysis
Fig. 31 RNA Therapy Clinical Trials Market: Therapeutic Areas segment dashboard
Fig. 32 RNA Therapy Clinical Trials Market: Therapeutic Areas outlook: Key takeaways
Fig. 33 Rare Diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Anti-infective market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Anticancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Neurological market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Alimentary/Metabolic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Cardiovascular Respiratory market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Sensory market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Global RNA Therapy Clinical Trials market, 2018 - 2030 (USD Million)
Fig. 43 North America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 44 U.S. RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 45 Canada RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 46 Europe RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 47 UK RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 48 Germany RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 49 France RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 50 Italy RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 51 Spain RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 52 Sweden RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 53 Norway RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 54 Denmark RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 55 Asia Pacific RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 56 Japan RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 57 China RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 58 India RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 59 Australia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 60 South Korea RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 61 Thailand RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 62 Latin America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 63 Brazil RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 64 Mexico RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 65 Argentina RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 66 MEA RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 67 South Africa RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 68 Saudi Arabia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 69 UAE RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 70 Kuwait RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 71 Heat map analysis
Fig. 72 Market differentiator

Companies Mentioned

  • IQVIA
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace Holdings, Inc.
  • PPD Inc.
  • Novotech
  • Veristat, LLC.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedJuly 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 2.56 billion
Forecasted Market Value ( USD ) by 2030 $ 3.5 billion
Compound Annual Growth Rate3.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route of Administration (Intrathecal, Intravenous), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route of Administration (Intrathecal, Intravenous), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 130 Pages
  • Global
From
Global Messenger RNA - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Global Messenger RNA - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Global Messenger RNA (mRNA)-based Vaccines and Therapeutics - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
RNA Therapy Market by Technology, Indication, End User - Global Forecast 2025-2030 - Product Image

RNA Therapy Market by Technology, Indication, End User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.